Early attempts, including farnesyltransferase inhibitors (FTIs), failed in KRAS-driven cancers owing to compensatory alternative prenylation, reinforcing its reputation as “undruggable.” However, advances in structural biology and biochemical analyses uncovered mutation-specific vulnerabilities, particularly in the KRAS G12C mutant. The gene discussed is KRAS; the disease is cancer.